Evan Loh Paratek Pharmaceuticals, Inc. (PRTK) insider trading activity

PRTK Quotes by TradingView

Evan Loh is CEO of Paratek Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of PRTK, which is worth approximately $0. The most recent transaction as insider was on Sep 21, 2023, when has been sold 1,327,981 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Evan Loh Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 21 2023
SELL
Sale (or disposition) back to the issuer
-
1,327,981 Reduced 100.0%
0 Common Stock
Aug 09 2023
SELL
Open market or private sale
$107,727 $2.2 p/Share
48,967 Reduced 3.56%
1,327,981 Common Stock
Aug 08 2023
BUY
Grant, award, or other acquisition
-
168,750 Added 10.92%
1,376,948 Common Stock
Dec 21 2022
SELL
Open market or private sale
$46,743 $1.99 p/Share
23,489 Reduced 1.91%
1,208,198 Common Stock
Dec 20 2022
BUY
Grant, award, or other acquisition
-
52,500 Added 4.09%
1,231,687 Common Stock
Dec 13 2022
SELL
Open market or private sale
$121,361 $1.96 p/Share
61,919 Reduced 4.99%
1,179,187 Common Stock
Dec 12 2022
SELL
Open market or private sale
$74,905 $1.98 p/Share
37,831 Reduced 2.96%
1,241,106 Common Stock
Oct 28 2022
SELL
Open market or private sale
$30,553 $3.47 p/Share
8,805 Reduced 0.68%
1,278,937 Common Stock
Oct 25 2022
BUY
Grant, award, or other acquisition
-
30,000 Added 2.28%
1,287,742 Common Stock
Aug 09 2022
SELL
Open market or private sale
$118,421 $2.66 p/Share
44,519 Reduced 3.42%
1,257,742 Common Stock
Aug 08 2022
BUY
Grant, award, or other acquisition
-
152,727 Added 10.5%
1,302,261 Common Stock
Mar 15 2022
BUY
Grant, award, or other acquisition
-
236,250 Added 17.05%
1,149,534 Common Stock
Dec 15 2021
SELL
Open market or private sale
$210,336 $4.27 p/Share
49,259 Reduced 5.12%
913,284 Common Stock
Dec 14 2021
SELL
Open market or private sale
$104,155 $4.37 p/Share
23,834 Reduced 2.42%
962,543 Common Stock
Dec 13 2021
SELL
Open market or private sale
$61,805 $4.42 p/Share
13,983 Reduced 1.4%
986,377 Common Stock
Aug 17 2021
SELL
Open market or private sale
$173,727 $5.12 p/Share
33,931 Reduced 3.28%
1,000,360 Common Stock
Aug 16 2021
BUY
Grant, award, or other acquisition
-
75,000 Added 6.76%
1,034,291 Common Stock
Jun 04 2021
SELL
Open market or private sale
$355,544 $9.7 p/Share
36,654 Reduced 3.68%
959,291 Common Stock
May 27 2021
BUY
Grant, award, or other acquisition
-
91,636 Added 8.43%
995,945 Common Stock
Mar 30 2021
BUY
Grant, award, or other acquisition
-
303,750 Added 25.14%
904,309 Common Stock
Dec 14 2020
SELL
Open market or private sale
$177,245 $6.71 p/Share
26,415 Reduced 4.21%
600,559 Common Stock
Dec 11 2020
SELL
Open market or private sale
$129,166 $6.95 p/Share
18,585 Reduced 2.88%
626,974 Common Stock
Nov 13 2020
SELL
Open market or private sale
$124,103 $5.93 p/Share
20,928 Reduced 3.14%
645,559 Common Stock
Nov 12 2020
BUY
Grant, award, or other acquisition
-
75,000 Added 10.11%
666,487 Common Stock
Oct 29 2020
BUY
Exercise of conversion of derivative security
$169,760 $4.3 p/Share
39,479 Added 6.26%
591,487 Common Stock

Also insider at

EIGR
Eiger BioPharmaceuticals, Inc. Healthcare
WINT
WINDTREE THERAPEUTICS INC Healthcare
Director
EL

Evan Loh

CEO
Boston, MA

Track Institutional and Insider Activities on PRTK

Follow Paratek Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRTK shares.

Notify only if

Insider Trading

Get notified when an Paratek Pharmaceuticals, Inc. insider buys or sells PRTK shares.

Notify only if

News

Receive news related to Paratek Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on PRTK